← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ptc Therapeutics, Inc.
South Plainfield, NJ
$11,982,285
Total funding
19
Grants
Funding over time
peak $1.9M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$7,382,585 · 13
FDA$4,302,812 · 5
DOD$296,888 · 1
By mechanism
R01$4,302,812 · 5
R44$2,936,933 · 3
R42$1,467,514 · 2
R56$1,082,325 · 1
RC1$996,430 · 1
R43$772,823 · 5
Investigators at Ptc Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Discovery of antiviral agents targeting dengue viral translation$1,082,325
R56 · FY2012 · AI
Development of an inhibitor of VEGF expression$740,577
R44 · FY2006 · CA
Development of an inhibitor of VEGF expression$719,008
R44 · FY2005 · CA
Developing antiviral agents that inhibit HCV translation$652,409
R44 · FY2005 · AI
Developing antiviral agents that inhibit HCV translation$652,409
R44 · FY2004 · AI
Phase 2a Study of Ataluren in Hemophilia A and B (IND 104,321)$498,215
RC1 · FY2010 · HL
Phase 2a Study of Ataluren in Hemophilia A and B (IND 104,321)$498,215
RC1 · FY2009 · HL
PTC124 as a Therapy for Non-Sense Mutation Mediated Cystic Fibrosis$478,398
R01 · FY2006 · FD
Mechanism of nonsense mutation suppression therapy$444,298
R42 · FY2007 · HD
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2013 · FD
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2010 · FD
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2012 · FD
Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)$399,984
R01 · FY2011 · FD
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2010 · FD
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2009 · FD
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2011 · FD
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2012 · FD
Mechanism of nonsense mutation suppression therapy$364,241
R42 · FY2006 · HD
PHASE 2, OPEN-LABEL, ACTIVITY, PHARMACODYNAMIC, PHARMACOKINETIC, AND SAFETY STUDY OF PTC299 IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2$296,888
· FY2009 · Department of Defense
PHASE 2 STUDY OF PTC124 AS AN ORAL TREATMENT FOR NONSEN*$279,225
R01 · FY2007 · FD